Skip to main content
. 2012 Apr 27;61(11):2045–2054. doi: 10.1007/s00262-012-1224-6

Fig. 7.

Fig. 7

Evaluation of the new immunotherapy to treat FBL3 cancer. a Tumor sizes and growth rates in mice treated with PBS, GM3NPhAc-KLH/PBS, and GM3NPhAc-KLH/ManNPhAc, respectively. *P < 0.001, as compared to the other two treatment groups. b Survival time of tumor-bearing mice treated with PBS, GM3NPhAc-KLH/PBS, and GM3NPhAc-KLH/ManNPhAc, respectively. The average survival time of mice treated with GM3NPhAc-KLH/ManNPhAc (>40.1 days) was significantly longer than that of the other two groups (25.3 days for PBS group, 32.0 days for GM3NPhAc-KLH/PBS group)